NDLI: Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia

Content Provider	Springer Nature : BioMed Central
Author	Ruseckaite, Rasa Sampurno, Fanny Millar, Jeremy Frydenberg, Mark Evans, Sue
Abstract	Background Men diagnosed with prostate cancer (PCa) in specific regional areas in Victoria, Australia have a poorer five-year survival rate compared to men living elsewhere in Victoria. This study aims to describe patterns-of- presentation and -care for men diagnosed with PCa in a specific regional Victorian area, and compare the outcomes with other Victorian regions. Methods Information on consecutive men diagnosed between 2008 and 2013 was extracted from the Prostate Cancer Outcomes Registry-Victoria. Descriptive analyses summarized diagnostic and treatment patterns of the 7,204 men with PCa in the selected region (n = 373), metropolitan Melbourne (n = 2,565) and remaining areas of Victoria (n = 4,266) to compare risk factors, treatments and time-taken-to-treatment. Results Men with PCa in the selected region were more likely to be diagnosed at older age (aged 68.6 vs 66 years in the rest of Victoria), and incidentally rather than through case-finding PSA blood tests. They were more likely to be presented with higher NCCN risk of the disease (High: 26 %, 24 % and 20.3 %; Very high/Metastasis: 11.8 %, 5.2 % and 5.7 % in the study region, metropolitan Melbourne and elsewhere in Victoria, respectively). Men in the selected region were also more likely to have a longer time from diagnosis to treatment (on average 15–30 days longer when compared to the rest of Victoria). Conclusions Poorer outcomes of men with PCa in this specific region might be explained by multiple factors, including clinical-, patient-, and health-system-related. This range of explanatory factors, occurring at multiple points along the pathway of diagnosis and detection, suggests that interventions to improve outcomes for PCa in regional areas such as this need to be systematic. Interventions specifically addressing any one factor in isolation are unlikely to have much effect.
Related Links	https://bmcurol.biomedcentral.com/counter/pdf/10.1186/s12894-016-0172-4.pdf
Ending Page	10
Page Count	10
Starting Page	1
File Format	HTM / HTML
ISSN	14712490
DOI	10.1186/s12894-016-0172-4
Journal	BMC Urology
Issue Number	1
Volume Number	16
Language	English
Publisher	BioMed Central
Publisher Date	2016-09-02
Access Restriction	Open
Subject Keyword	Urology Internal Medicine Prostate cancer Regional Clinical registry Patterns-of-care
Content Type	Text
Resource Type	Article
Subject	Urology Reproductive Medicine
Journal Impact Factor	1.7/2023
5-Year Journal Impact Factor	2/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry

Trends of prostate cancer treatment in Ehime Prefecture, Japan: analysis of a hospital-based cancer registry

Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study

Overexpression of DDX49 in prostate cancer is associated with poor prognosis

Characterization of metabolism-associated molecular patterns in prostate cancer

Patient-reported functional outcome measures and treatment choice for prostate cancer

Prognostic value of changes in quality of life scores in prostate cancer

Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry

Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia

Similar Documents

Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry

Trends of prostate cancer treatment in Ehime Prefecture, Japan: analysis of a hospital-based cancer registry

Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study

Overexpression of DDX49 in prostate cancer is associated with poor prognosis

Characterization of metabolism-associated molecular patterns in prostate cancer

Patient-reported functional outcome measures and treatment choice for prostate cancer

Prognostic value of changes in quality of life scores in prostate cancer

Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry

Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia